Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780500 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07780500 · ClinicalTrials.gov record · last posted 2026-08-21

REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension

Name: REFOCUS-HTN US-WEST: A Data Infrastructure to Characterize Individuals With Hypertension — clinical trial record (NCT07780500)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REFOCUS-HTN

StatusRecruiting

PhaseNot specified

SponsorKaiser Permanente

Started2026-08-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The goal of the REFOCUS-HTN US-WEST program is to gain a better understanding of the role of a hormone called aldosterone in the development of hypertension. The SCALED sub-study is an observational cohort study that will enroll from REFOCUS-HTN cohort for prospective data collection.

Trial Details

NCT Number	NCT07780500
Lead Sponsor	Kaiser Permanente Collaborators: AstraZeneca
Conditions	Hypertension, Aldosterone Disorder, Cardiovascular Disease (CVD)
Enrollment	500 participants
Start Date	2026-08-20
Primary Completion	2028-03 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-21